A 2025 medical study concluded that there is an increased risk of NAION associated with Ozempic and Mounjaro. In more detail, the researchers considered whether treatment with either Ozempic (semaglutide) or Mounjaro (tirzepatide) is associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) when compared to other antidiabetic medications.
The medical journal article about this recent medical study published in August 2025 had an important drug safety bottom-line statement: “In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed [Ozempic (semaglutide)] or [Mounjaro (tirzepatide)] had an increased risk of NAION…”.
From the Discussion part of this recent medical journal article published August 11, 2025, online by JAMA Network Open, “Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes“:
In a population of patients with type 2 diabetes who had no prior diagnosis of eye diseases, this cohort study found that semaglutide [(Ozempic)] or tirzepatide [(Mounjaro)] compared with other antidiabetic medications was associated with a differential risk of optic nerve and visual pathways, including increased risk of NAION and other optic nerve disorders, but not optic neuritis, papilledema, optic atrophy, or optic disc orders. Cumulative incidence curves began to diverge immediately after medication initiation and continued to separate thereafter.
Related to the increased risk of NAION associated with Ozempic and Mounjaro findings, there are additional drugs used for obesity and weight loss purposes that contain semaglutide (Wegovy, Rybelsus) or tirzepatide (Zepbound). As we have covered in earlier articles, there is some evidence that the NAION eye-related side effect is associated with those additional drugs, too.
We will continue to follow the NAION (non-arteritic anterior ischemic optic neuropathy) associated with Ozempic (semaglutide) and Mounjaro (tirzepatide) drug safety issues, as well as whether the two other semaglutide-containing drugs (Wegovy, Rybelsus) and the one other tirzepatide-containing drug (Zepbound) are associated with an increased risk of NAION.
[View article at original source]Ozempic / Rybelsus / Wegovy
Free Case Evaluation
Strictly Confidential, No Obligation
Mounjaro / Zepbound
Free Case Evaluation
Strictly Confidential, No Obligation